NCT06174363 Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
| NCT ID | NCT06174363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2023-12-28 |
| Primary Completion | 2025-12-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 84 participants in total. It began in 2023-12-28 with a primary completion date of 2025-12-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.
Eligibility Criteria
Inclusion Criteria: * Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction) Exclusion Criteria: * ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06174363 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 70 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06174363 currently recruiting?
Yes, NCT06174363 is actively recruiting participants. Contact the research team at chjs0214@yuhs.ac for enrollment information.
Where is the NCT06174363 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06174363 clinical trial?
NCT06174363 is sponsored by Yonsei University. The trial plans to enroll 84 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.